Esther de Boer

Artiklar

Article: TRANSFUSION. 2025;65(6):1132-1144
Vesiculation as potential novel pathogenic mechanism in autoimmune hemolytic anemia.
de Boer ECW; Mulder FVM; Neri S; Wiskerke-van Stuijvenberg M; Arts JJG; Tol S; Beuger B; Bosman MCJ; Thielen N; van der Griend R; Folman CC; de Haas M; van Bruggen R; Pouw RB; Vos JMI
Article: BLOOD ADVANCES. 2023;7(13):3128-3139
C1-inhibitor treatment in patients with severe complement-mediated autoimmune hemolytic anemia.
de Boer ECW; Jalink M; Delvasto-Nuñez L; Meulenbroek EM; Baas I; Janssen SR; Folman CC; Gelderman KA; Wouters D; Engel MD; de Haas M; Kersten MJ; Jongerius I; Zeerleder S; Vos JMI
Article: CLINICAL & TRANSLATIONAL IMMUNOLOGY. 2023;12(1):e1436
The contribution of the alternative pathway in complement activation on cell surfaces depends on the strength of classical pathway initiation.
de Boer EC; Thielen AJ; Langereis JD; Kamp A; Brouwer MC; Oskam N; Jongsma ML; Baral AJ; Spaapen RM; Zeerleder S; Vidarsson G; Rispens T; Wouters D; Pouw RB; Jongerius I

Letter: CLINICAL GASTROENTEROLOGY AND HEPATOLOGY. 2025;23(7):1264-1267.e3
A Pedigree With Complement Hyperactivation, Angiopathic Thrombosis, and Severe Protein-losing Enteropathy (CHAPLE) Disease: Variable Penetrance and Treatment With Pozelimab.
De Boer ECW; Van Der Kruk N; Pouw RB; Van Limbergen JE; Kuijpers TW
Review: SEMINARS IN IMMUNOPATHOLOGY. 2021;43(6):799-816
Halting targeted and collateral damage to red blood cells by the complement system.
Jalink M; de Boer ECW; Evers D; Havinga MQ; Vos JMI; Zeerleder S; de Haas M; Jongerius I
Review: PHARMACOLOGICAL RESEARCH. 2020;159:105038
Ephrin-Eph signaling usage by a variety of viruses.
de Boer ECW; van Gils JM; van Gils MJ
Review: FRONTIERS IN IMMUNOLOGY. 2020;11:578069
Therapeutic Lessons to be Learned From the Role of Complement Regulators as Double-Edged Sword in Health and Disease.
de Boer ECW; van Mourik AG; Jongerius I